GSK expanded its 2020 collaboration with Vir Biotechnology by paying $120M upfront plus $225M for new respiratory virus programs (~$345M total) to add influenza and other respiratory virus antibody programs alongside the ongoing sotrovimab COVID-19 program with 72.5/27.5 GSK/Vir profit share.
Key facts
AnnouncedApr 19, 2021
Deal value$345M
Deal typeCo-Development
Therapeutic areaCOVID-19, influenza, other respiratory viruses
IndicationsCOVID-19, influenza, other respiratory viruses
Key assetsSotrovimab (VIR-7831) and respiratory virus antibodies
MechanismNeutralizing monoclonal antibodies (sotrovimab is anti-SARS-CoV-2 spike protein)